Elite Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Elite Pharmaceuticals, Inc. (ELTP) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 4.27% for the 12-month period ending 2024-03-31, per its 10-K filed 2025-06-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2025-06-30
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2023-09-30 was 4.27%.
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2018-06-30 was 2.20%, a 0.00% change year-over-year.
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2017-06-30 was 2.20%.
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2024 was 4.27%, a 42.81% increase from fiscal 2023.
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2023 was 2.99%.
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2018 was 2.20%, a 46.67% increase from fiscal 2017.
- Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2017 was 1.50%, a 28.57% decline from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month |
|---|---|---|---|---|
| 2024-03-31 | 4.27% 10-K · filed 2025-06-30 | |||
| 2023-12-31 | 4.27% 10-Q · filed 2024-02-14 | |||
| 2023-09-30 | 4.27% 10-Q · filed 2023-11-14 | 4.27% 10-Q · filed 2023-11-14 | ||
| 2023-03-31 | 2.99% 10-K · filed 2024-07-01 | |||
| 2018-06-30 | 2.20% 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | 2.20% 10-K · filed 2019-06-21 | |||
| 2017-12-31 | 2.20% 10-Q · filed 2018-02-09 | |||
| 2017-09-30 | 2.20% 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | 2.20% 10-Q · filed 2017-08-09 | |||
| 2017-03-31 | 1.50% 10-K · filed 2018-06-14 | |||
| 2016-12-31 | 1.80% 10-Q · filed 2017-02-09 | |||
| 2016-09-30 | 1.50% 10-Q · filed 2016-11-09 | |||
| 2016-03-31 | 2.10% 10-K · filed 2018-06-14 | |||
| 2015-03-31 | 2.20% 10-K · filed 2017-06-14 |